Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0023418 (
leukemia
)
93,477
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
ARTS
(Sept4_i2) is a mitochondrial pro-apoptotic protein that functions as a tumor suppressor. Its expression is significantly reduced in
leukemia
and lymphoma patients.
ARTS
binds and inhibits XIAP (X-linked Inhibitor of Apoptosis protein) by interacting with its Bir3 domain.
ARTS
promotes degradation of XIAP through the proteasome pathway. By doing so,
ARTS
removes XIAP inhibition of caspases and enables apoptosis to proceed.
ARTS
contains 27 unique residues in its C-terminal domain (CTD, residues 248-274) which are important for XIAP binding. Here we characterized the molecular details of this interaction. Biophysical and computational methods were used to show that the
ARTS
CTD is intrinsically disordered under physiological conditions. Direct binding of
ARTS
CTD to Bir3 was demonstrated using NMR and fluorescence spectroscopy. The Bir3 interacting region in
ARTS
CTD was mapped to
ARTS
residues 266-274, which are the nine C-terminal residues in the protein. Alanine scan of
ARTS
266-274 showed the importance of several residues for Bir3 binding, with His268 and Cys273 contributing the most. Adding a reducing agent prevented binding to Bir3. A dimer of
ARTS
266-274 formed by oxidation of the Cys residues into a disulfide bond bound with similar affinity and was probably required for the interaction with Bir3. The detailed analysis of the
ARTS
- Bir3 interaction provides the basis for setting it as a target for anti cancer drug design: It will enable the development of compounds that mimic
ARTS
CTD, remove IAPs inhibition of caspases, and thereby induce apoptosis.
...
PMID:Mechanism of the interaction between the intrinsically disordered C-terminus of the pro-apoptotic ARTS protein and the Bir3 domain of XIAP. 2194 40